CORT Corcept Therapeutics Incorporated

18.20
+0.69  (4%)
Previous Close 17.51
Open 17.41
Price To book 31.38
Market Cap 2063839978
Shares 113,397,801
Volume 1,582,029
Short Ratio 5.12
Av. Daily Volume 1,260,403

SEC filingsSee all SEC filings

  1. 8-K - Current report 171059367
  2. 8-K - Current report 171012541
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17997814
  4. 8-K - Current report 17996827
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17908987

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 2 ongoing.
Mifepristone plus Abraxane
Triple-negative breast cancer
Phase 2 ongoing.
Mifepristone plus enzalutamide
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data released December 10, 2016 - 4/21 partial responses.
Mifepristone in combination with eribulin
Cancer - triple-negative breast cancer
Phase 2 initiated 1Q 2016. Enrolling as of August 2017.
CORT125134
Solid tumors - cancer
Phase 2 trial initiated 2Q 2016. Data due 1Q 2018.
CORT125134
Cushing’s syndrome